Prostate Cancer
is the most common cancer in men and the second leading cause of cancer-related death in men. We discover and develop novel circulating and tissue-based biomarkers to inform clinical decisions in the management of patients with localized and metastatic prostate cancer.
Bladder Cancer
is the fifth most common cancer in the US, causing 18,000 deaths per year. We analyze biospecimens from bladder cancer patients to understand molecular determinants of therapeutic response and discover biomarkers to guide and monitor bladder cancer therapy.
Circulating Tumor Cells (CTCs)
are rare cancer cells shed into the blood stream. CTCs are a type of “liquid biopsy” that can be used to monitor therapy, predict treatment response, and potentially detect cancer early. We have developed microfluidic technologies to efficiently isolate and analyze rare CTCs from blood.